An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
NCT02845674
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
258
Enrollment
INDUSTRY
Sponsor class
Conditions
Keratoconjunctivitis Sicca
Interventions
DRUG:
OTX-101 0.09%
Sponsor
Sun Pharmaceutical Industries Limited